AIV Logo AIV Assistant

Loading...

 Logo Arcutis Biotherapeutics, Inc. - ARQT Open Arcutis Biotherapeutics, Inc. in new tab

24.92
EPS
-0.73
P/B
16.93
ROE
-0.57
Beta
2.07

24.9200

24.920

Daily: -1.46%
Key Metrics

Earnings date: Feb. 24, 2026

EPS: -0.73

Book Value: 1.16

Price to Book: 16.93

Debt/Equity: 79.27

% Insiders: 0.019%

Growth

Revenue Growth: 1.64%

Estimates

Forward P/E: -20.04

Forward EPS: -0.98

 Logo About Arcutis Biotherapeutics, Inc. - (ARQT)

Country: United States

Sector: Health Care

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE foam for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-255, a selective small molecule inhibitor of JAK1 for the treatment of alopecia areata; ARQ-252, a JAK1-selective topical cream in development for hand eczema and vitiligo; and ARQ-234, a CD200R fusion protein for the treatment of atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.

Dividends

Historical Split Corporate Actions

Trades
My Trades
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion